Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON NASDAQ:IMRX NASDAQ:NBTX NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.75+2.4%$2.52$1.60▼$3.16$1.05B1.122.02 million shs222,700 shsIMRXImmuneering$6.51+0.1%$5.83$1.10▼$10.08$270.41M0.471.47 million shs99,045 shsNBTXNanobiotix$27.11-0.7%$11.29$2.76▼$27.77$1.29B0.724,334 shs39,829 shsUPBUpstream Bio$18.94+0.1%$17.50$5.14▼$29.46$1.02BN/A379,093 shs412 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+2.29%+0.75%+8.06%+27.62%+23.50%IMRXImmuneering+6.38%+2.20%+9.24%+50.12%+171.97%NBTXNanobiotix+30.19%+45.68%+213.43%+409.80%+423.24%UPBUpstream Bio+1.34%+1.56%+1.01%+59.80%+1,891,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.75+2.4%$2.52$1.60▼$3.16$1.05B1.122.02 million shs222,700 shsIMRXImmuneering$6.51+0.1%$5.83$1.10▼$10.08$270.41M0.471.47 million shs99,045 shsNBTXNanobiotix$27.11-0.7%$11.29$2.76▼$27.77$1.29B0.724,334 shs39,829 shsUPBUpstream Bio$18.94+0.1%$17.50$5.14▼$29.46$1.02BN/A379,093 shs412 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+2.29%+0.75%+8.06%+27.62%+23.50%IMRXImmuneering+6.38%+2.20%+9.24%+50.12%+171.97%NBTXNanobiotix+30.19%+45.68%+213.43%+409.80%+423.24%UPBUpstream Bio+1.34%+1.56%+1.01%+59.80%+1,891,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 1.00SellN/AN/AIMRXImmuneering 2.43Hold$16.40151.96% UpsideNBTXNanobiotix 2.25Hold$11.00-59.42% DownsideUPBUpstream Bio 2.60Moderate Buy$56.50198.31% UpsideCurrent Analyst Ratings BreakdownLatest IMRX, UPB, CRON, and NBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CRONCronos GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025IMRXImmuneeringWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NBTXNanobiotixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025UPBUpstream BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/30/2025IMRXImmuneeringHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.009/27/2025CRONCronos GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025IMRXImmuneeringWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NBTXNanobiotixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025UPBUpstream BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/26/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.009/25/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$21.00 ➝ $30.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.61M8.94$0.00 per share5,630.53$2.90 per share0.95IMRXImmuneeringN/AN/AN/AN/A$1.33 per shareN/ANBTXNanobiotix$39.18M33.17N/AN/A($1.51) per share-17.95UPBUpstream Bio$2.72M374.97N/AN/A$8.77 per share2.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.0554.9091.50N/A14.19%-3.78%-3.62%11/11/2025 (Estimated)IMRXImmuneering-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%11/12/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/AN/AUPBUpstream Bio-$62.81MN/A0.00N/AN/A-3,836.58%-35.90%-26.26%11/6/2025 (Estimated)Latest IMRX, UPB, CRON, and NBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025UPBUpstream Bio-$0.77N/AN/AN/A$0.65 millionN/A8/13/2025Q2 2025IMRXImmuneering-$0.40-$0.40N/A-$0.40N/AN/A8/7/2025Q2 2025CRONCronos Group-$0.02-$0.10-$0.08-$0.10$45.73 million$33.46 million8/6/2025Q2 2025UPBUpstream Bio-$0.61-$0.74-$0.13-$0.74$0.32 million$0.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.6523.53IMRXImmuneeringN/A3.703.70NBTXNanobiotixN/A0.63N/AUPBUpstream BioN/A38.2738.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%IMRXImmuneering67.65%NBTXNanobiotix38.81%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%IMRXImmuneering22.90%NBTXNanobiotix3.45%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450382.89 million354.94 millionOptionableIMRXImmuneering6041.57 million32.05 millionNot OptionableNBTXNanobiotix10047.94 million46.29 millionNot OptionableUPBUpstream Bio3853.91 million46.60 millionN/AIMRX, UPB, CRON, and NBTX HeadlinesRecent News About These CompaniesUpstream Bio management to meet with Piper SandlerOctober 7 at 10:08 PM | msn.comWilliam Blair Sticks to Their Buy Rating for Upstream Bio, Inc. (UPB)October 7 at 2:04 AM | theglobeandmail.comUpstream Bio (UPB): Assessing Valuation as Shares Climb 7% Over the Past WeekOctober 4, 2025 | finance.yahoo.comUpstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Buy" from BrokeragesOctober 3, 2025 | marketbeat.comUpstream Bio’s verekitug shows prevention of TSLP binding in respiratory diseaseSeptember 30, 2025 | msn.comUpstream Bio (NASDAQ:UPB) Trading 4.2% Higher - Still a Buy?September 30, 2025 | marketbeat.comUpstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European ...September 30, 2025 | finance.yahoo.comUpstream Bio, Inc. Presents Data on Verekitug's Mechanism of Action at ERS Congress, Highlighting Its Potential in Treating TSLP-Driven Severe Respiratory DiseasesSeptember 30, 2025 | quiverquant.comQUpstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society CongressSeptember 30, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Shares Down 5.3% - Here's What HappenedSeptember 18, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading 5.9% Higher - Still a Buy?September 17, 2025 | marketbeat.comUpstream Bio, Inc. (UPB): A Bull Case TheorySeptember 16, 2025 | msn.comTD Cowen Remains a Buy on Upstream Bio, Inc. (UPB)September 10, 2025 | theglobeandmail.comUpstream Bio Announces Positive Phase 2 Trial ResultsSeptember 9, 2025 | theglobeandmail.comUpstream Bio, Inc. CEO Rand Sutherland to Speak at Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 9, 2025 | quiverquant.comQUpstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 9, 2025 | globenewswire.comUpstream Bio, Inc. - Special CallSeptember 7, 2025 | seekingalpha.comUpstream Bio, Inc. (UPB) Special Call - SlideshowSeptember 5, 2025 | seekingalpha.comUpstream Bio Shares Rise on Positive Data for Sinus-Disease TreatmentSeptember 3, 2025 | marketwatch.comPositive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for VerekitugSeptember 2, 2025 | tipranks.comChasing pharma heavyweights, Upstream posts phase 2 sinusitis win but stock flows downhillSeptember 2, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Why Micron Stock Could Outperform NVIDIA in 2025By Gabriel Osorio-Mazilli | September 12, 2025Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming SoonBy Thomas Hughes | September 25, 2025IMRX, UPB, CRON, and NBTX Company DescriptionsCronos Group NASDAQ:CRON$2.74 +0.07 (+2.43%) As of 09:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Immuneering NASDAQ:IMRX$6.51 +0.01 (+0.14%) As of 09:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Nanobiotix NASDAQ:NBTX$27.11 -0.19 (-0.70%) As of 09:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Upstream Bio NASDAQ:UPB$18.99 +0.07 (+0.36%) As of 09:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
